Lv41
410 积分 2022-03-18 加入
The role of hydrophilic linkers in next-generation antibody-drug conjugates
5小时前
已完结
Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release
7天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
10天前
已完结
From the ESMO Congress 2025
10天前
已完结
Tarlatamab for small-cell lung cancer
10天前
已完结
Dual-payload ADCs move into first oncology clinical trials
24天前
已完结
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
25天前
已完结
OA06.01 A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC
1个月前
已关闭
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
1个月前
已完结
Irinotecan-induced interstitial pneumonia
1个月前
已完结
皖公网安备34019202002308
